Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Pregnancy can be an exciting time but for those living with rheumatic musculoskeletal diseases (RMDs), it can also be a time fraught with concern, including what effect pregnancy will have on the underlying RMD and what effect the RMD may have on the pregnancy and the baby, including the effects of medications. Generating an evidence base in pregnancy is challenging. Few interventional trials of medications in RMD pregnancies have ever been conducted, often for concerns of safety for both the mother and the child. Therefore, observational research remains important for informing clinical practice and helping women with RMDs make decisions regarding their health preconception and during pregnancy. The Annals of the Rheumatic Diseases (ARD) continues to publish important research on pregnancy in RMDs to increase the evidence base on this subject. Here we present an overview of papers published on this topic between January 2018 and December 2023. Our focus includes papers on pregnancy and RMD outcome, the effects of drug exposure, fetal outcomes as well as fertility.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/ard-2023-224861 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Annals of the rheumatic diseases collection on genetic studies of rheumatic diseases.
Ann Rheum Dis
September 2025
RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. Electronic address:
Social media landscape of rheumatology journals.
Rheumatol Int
September 2025
Department of Rheumatology, Immunology and Internal Medicine, University Hospital in Kraków, Kraków, Poland.
Introduction: Social media (SoMe) platforms provide ample opportunities for disseminating research results and journal updates. The presence of indexed rheumatology journals on SoMe has been scarcely explored.
Objectives: The purpose of this study is to assess the presence of mainstream rheumatology journals on key SoMe platforms and to analyze the relationship between bibliometric indicators and alternative metrics.
NLRP3 Inflammasome: A New Perspective on Revealing Hotspots and Trends in Uric Acid Metabolism Disorders through Bibliometric Analysis.
Endocr Metab Immune Disord Drug Targets
July 2025
School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing102488, China.
Uric acid metabolism disorders have become major health concerns, primarily causing conditions such as hyperuricemia, uric acid nephropathy, and gout. Recent research has focused on these disorders' underlying pathological mechanisms and pharmacological treatments, emphasizing the role of the NLRP3 inflammasome. This study aims to analyze and summarize the current research status, hotspots, and trends in this field from a new perspective of the NLRP3 inflammasome, providing insights for future research and disease treatment.
View Article and Find Full Text PDFA Real-World Comparison of Clinical Effectiveness of Upadacitinib, Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis After Switching from an Initial Tumor Necrosis Factor Inhibitor Treatment.
Rheumatol Ther
July 2025
Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, USA.
Introduction: Tumor necrosis factor inhibitors (TNFi) may have insufficient efficacy in 40% of patients with axial spondyloarthritis (axSpA), leading to continued pain. We aimed to compare real-world effectiveness of switching from an initial TNFi to upadacitinib (TNFi-UPA), another TNFi (TNFi-TNFi), or an interleukin-17 inhibitor (TNFi-IL-17i) in patients with axSpA.
Methods: Data were drawn from the Adelphi Real World Spondyloarthritis Disease Specific Programme™, a cross-sectional survey of physicians and their patients with axSpA in France, Germany, Italy, Spain, the UK, and the USA from March-November 2021 and June 2023-June 2024.
Discriminating capacity of the ASAS health index in patients with axial spondyloarthritis treated with ixekizumab.
Semin Arthritis Rheum
June 2025
Ruhr-Universität Bochum, Universitätsstraße 150, 44801 Bochum, Germany; RVZ Steglitz, Schloßstraße 110, 12163 Berlin, Germany.
Objective: To test the discriminating capacity of different thresholds of the Assessment of SpondyloArthritis international Society Health Index (ASAS HI) in placebo-controlled trials of patients with axial spondyloarthritis (axSpA), including radiographic (r-axSpA) and non-radiographic (nr-axSpA) subtypes.
Methods: The discriminating capacities of absolute (≥2.0-≥4.